Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 8/20 | 0.45 |
| ▸ | CTSS | P25774 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13306434 | 0.85 | TDP1 (0.53) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL14085304 | 0.84 | PTPN11 (0.48) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL19787903 | 0.83 | PTPN11 (0.44) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL939491 | 0.81 | PTPN11 (0.47) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL22770879 | 0.81 | TDP1 (0.46) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL659104 | 0.80 | TDP1 (0.52) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL13306409 | 0.80 | TDP1 (0.56) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL14404775 | 0.80 | CTSK (0.51) | MEN1GAAKMT2APTPN11CTSK | |
| SCHEMBL30464727 | 0.79 | CTSK (0.41) | MEN1GAAKMT2ACTSKCTSS | |
| SCHEMBL22796979 | 0.79 | MAOA (0.49) | MEN1GAAKMT2APTPN11CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403459-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | MEN1 1533/4885GAA 1943/4885KMT2A 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.